Gabrielle Lakusta

Gabrielle grew up in the Lower Mainland of B.C. and has lived in Vancouver since 2011. She holds an Associate of Arts Degree from Langara College, and a Bachelors of Arts Major in Journalism from Kwantlen Polytechnic University. Now, she writes for INN focusing on Life Science Investing. Aside from work, Gabrielle enjoys travelling, and enjoying the outdoors—especially when hiking and cycling.

glakusta@resourceinvestingnews.com

Articles

Kiniksa Pharmaceuticals Announces Proposed Public Offering and Concurrent Private Placement

Kiniksa Pharmaceuticals (Nasdaq:KNSA) announced today that it is commencing a public offering of 8,000,000 Class A common shares. In addition,...

January 29th, 2019

Cyclacel Ready for More Clinical Data After Positive 2018

Spiro Rombotis and Paul McBarron of Cyclacel Pharmaceuticals discuss the company's pipeline, indications, clinical data and more.

January 28th, 2019

Allogene Therapeutics in Collaboration with Servier Announces FDA Clearance of the IND for ALLO-501

Allogene Therapeutics (Nasdaq:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, in...

January 28th, 2019

New Clinical Trial Finds Milestone Scientific’s CompuFlo Instrument a Safe Alternative to Current Standards of Care

Milestone Scientific (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the...

January 28th, 2019

Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint

Bellerophon Therapeutics (Nasdaq:BLPH) a clinical-stage biotherapeutics company, today announced that data from the Company’s ongoing INOpulse Phase 2b clinical trial...

January 28th, 2019

MacroGenics Announces Removal of Partial Clinical Hold on MGD009 Program by FDA

MacroGenics (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,...

January 28th, 2019

Expert: Is Alzheimer’s a Singular Disease?

Casey Lynch, CEO of Cortexyme, shares her take on a panel on Alzheimer’s disease at the Biotech Showcase, as well...

January 25th, 2019